See the DrugPatentWatch profile for litfulo
No, Litfulo is not approved for hair loss.
What Litfulo treats
Litfulo (ritlecitinib) is an FDA-approved oral kinase inhibitor for treating severe alopecia areata in adults and adolescents 12 years and older.[1] Alopecia areata causes patchy hair loss due to an autoimmune attack on hair follicles, and Litfulo targets JAK3 and TEC kinases to reduce inflammation and promote hair regrowth. Approval came in June 2023 based on the ALLEGRO phase 2b/3 trial, where 23% of patients on 50 mg achieved ≥80% scalp hair coverage at 24 weeks versus 1.6% on placebo.[1][2]
Does it work for other hair loss types?
Litfulo lacks approval or robust data for androgenetic alopecia (male/female pattern baldness), telogen effluvium, or scarring aloes. Its trials focused solely on severe alopecia areata (SALT score ≥50).[2] Off-label use for other types occurs anecdotally but carries risks without proven efficacy.
How does it compare to other hair loss drugs?
Unlike minoxidil or finasteride (approved for pattern baldness), Litfulo addresses autoimmune hair loss specifically. Olumiant (baricitinib), another JAK inhibitor, is approved for severe alopecia areata in adults.[3] Litfulo offers a once-daily pill with potentially fewer drug interactions.
Common side effects and patient concerns
Patients report headaches (14%), diarrhea (10%), acne (7%), and infections (higher UTI risk).[1] Long-term risks include serious infections, malignancies, and cardiovascular events due to JAK inhibition—black box warnings apply. It's not recommended during pregnancy or breastfeeding.
Availability and cost
Pfizer markets Litfulo; a 30-day supply (50 mg) costs about $2,500 without insurance.[4] Patient assistance programs exist via Pfizer's site.
[1]: FDA Label for Litfulo
[2]: NEJM: ALLEGRO Trial Results
[3]: FDA: Olumiant Approval
[4]: Drugs.com Pricing